Posted by Michael Wonder on 17 Nov 2020
Genentech files to block marketing of Centus' bevacizumab biosimilar
18 November 2020 - The reference product rights holder contends that Centus has not provided complete information about its manufacturing processes related to FKB238, the proposed biosimilar.
Genentech has filed suit attempting to block the anticipated sale in the United States of a bevacizumab biosimilar by Centus Biotherapeutics, a joint venture between Fujifilm Kyowa Kirin Biologics and AstraZenenca.
